Tech Company Financing Transactions
Aignostics Funding Round
Athos, Boehringer Ingelheim Venture Fund and Carma Fund invested in a $34 million Series B funding round for Aignostics. The round closed on 10/29/2024.
Transaction Overview
Company Name
Announced On
10/29/2024
Transaction Type
Venture Equity
Amount
$34,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to build new product offerings for biopharmaceutical clients, accelerate growth within the United States (US), and develop foundation models for pathology in collaboration with Mayo Clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Alt-Moabit 73
Berlin, 10555
DE
Berlin, 10555
DE
Phone
Undisclosed
Website
Email Address
Overview
Aignostics started in 2018 within the walls of Charité Berlin and the Berlin Institute of Health, based on years of research conducted by the pathology department of Charité, TU Berlin and Fraunhofer HHI. Following initial incubation, we spun-out of Charité and BIH in 2020, and are now focusing on pioneering computational pathology for pharmaceutical research, clinical trials and CDx development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Viktor Matyas
Chief Technical Officer
Aximilian Alber
Co-Founder
Frederick Klauschen
Co-Founder
Klaus-Robert Müller
Browse more venture capital transactions:
Prev: 10/29/2024: Beamery venture capital transaction
Next: 10/29/2024: Alimetry venture capital transaction
Share this article
Where The Data Comes From
We do our best to document tech company VC transactions. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs